BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22210098)

  • 1. A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer.
    César IC; Cunha-Júnior GF; Duarte Byrro RM; Vaz Coelho LG; Pianetti GA
    Ther Drug Monit; 2012 Feb; 34(1):59-66. PubMed ID: 22210098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma.
    Coudoré F; Roche D; Lefeuvre S; Faussot D; Billaud EM; Loriot MA; Beaune P
    J Chromatogr Sci; 2012; 50(10):877-84. PubMed ID: 22689904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.
    Déporte R; Amiand M; Moreau A; Charbonnel C; Campion L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 834(1-2):170-7. PubMed ID: 16545990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
    Jacobs BA; Rosing H; de Vries N; Meulendijks D; Henricks LM; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2016 Jul; 126():75-82. PubMed ID: 27179185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
    Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
    Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
    Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice.
    Remaud G; Boisdron-Celle M; Hameline C; Morel A; Gamelin E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):98-107. PubMed ID: 16027050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
    Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
    Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
    Kosovec JE; Egorin MJ; Gjurich S; Beumer JH
    Rapid Commun Mass Spectrom; 2008; 22(2):224-30. PubMed ID: 18085512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative determination of zidovudine diaryl phosphate triester pro-drugs in rat plasma by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry.
    Zhu M; Xie B; Tang G; Hu A; Fang M; Wu Z; Zhao Y
    J Pharm Biomed Anal; 2008 Dec; 48(5):1417-24. PubMed ID: 19118970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
    Zou JJ; Bian XJ; Ding L; Zhu YB; Fan HW; Xiao DW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jan; 861(1):151-7. PubMed ID: 18069077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
    Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
    Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of triamcinolone in human plasma by a sensitive HPLC-ESI-MS/MS method: application for a pharmacokinetic study using nasal spray formulation.
    César IC; Byrro RM; de Santana e Silva Cardoso FF; Mundim IM; de Souza Teixeira L; de Sousa WC; Gomes SA; Bellorio KB; Brêtas JM; Pianetti GA
    J Mass Spectrom; 2011 Mar; 46(3):320-6. PubMed ID: 21394848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity.
    Serdar MA; Sertoğlu E; Uyanık M; Tapan S; Akın O; Cihan M
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):525-9. PubMed ID: 21107571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
    Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
    Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
    Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
    Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers.
    Xu P; Li HD; Chen BM; Ma N; Yan M; Zhu YG
    J Pharm Biomed Anal; 2008 Aug; 47(4-5):994-9. PubMed ID: 18514457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.